Navigation Links
Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
Date:5/29/2008

rtunities to accelerate the timing of pediatric filings of the vaccine in the rest of the world from its current target of the first quarter of 2009. Wyeth's investigational 13-valent pneumococcal conjugate vaccine is being studied in Phase 3 global clinical trials in both infants and adults.

Wyeth recently has achieved significant success in bringing new products to market. In the first quarter of 2008 alone, Wyeth obtained three new product approvals in the following therapeutic areas: major depressive disorder, Hemophilia A and opioid-induced constipation.

Pneumococcal Disease

According to the World Health Organization (WHO), pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age. Due to the significant burden of pneumococcal disease and demonstrated vaccine efficacy, WHO recommends the priority inclusion of PCV7 in national childhood immunization programs worldwide. WHO notes that once other pneumococcal vaccines offering broader protection become available, countries can assess whether it would be helpful to switch to these vaccines.

Pneumococcal disease affects both children and adults and is a leading cause of illness and death worldwide. Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae and describes a group of illnesses, including invasive infections, such as bacteremia/sepsis and meningitis, as well as pneumonia and upper respiratory tract infections, including otitis media.

Important Safety Information about PREVNAR

In clinical trials (n=18,168), the most frequently reported adverse events included injection site reactions, fever (greater than or equal to 38 degrees C/100.4 degrees F), irritability, drowsiness, restless sleep, decreased appetite, vomiting, diarrhea, and rash. Risks are associated with all vaccines, including PREVNAR. Hypersensitivity to any vaccine component, including diphtheria toxoid, is a contraindication to its
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
2. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
3. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
4. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
7. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
11. Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Revenue and earnings above ... research and development In the past 2013/14 fiscal ... two percent to EUR 4.287 billion (last year: EUR 4.190 ... percent to EUR 360 million. "Overall, 2013/14 was a successful ... Kaschke , President and CEO of Carl Zeiss AG. "Thanks ...
(Date:12/17/2014)... , The new ... of information concerning the biopharmaceutical Group,s national and international clinical ... to the recently launched institutional website that is receiving accolades ... by a new chapter in the fascinating story of Drug ... and panoramic hub on the world of clinical research, ranging ...
(Date:12/17/2014)... -- PCCA received the Autism Hope Alliance,s (AHA) ... seal for best practices in meeting needs in ... materials and goods that meet strict criteria and ... by autism often have unique physical or psychological ... in food and medicine – for instance casein, ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... 4 NovaRx Corporation announced today the appointment of ... and Chief Operating Officer. Dr. Russell brings to ... discovery and a long history of success driving innovation ... experience leading entrepreneurial biotechnology companies developing pioneering new technologies. ...
... - Tasigna front-line data demonstrating potential in newly diagnosed patients with ... sessions at ASH , , - ... by significantly reducing toxic iron that can damage key organs , ... major independent breast cancer trial at SABCS to report on optimal ...
Cached Medicine Technology:NovaRx Appoints Industry Veteran as President and COO 2NovaRx Appoints Industry Veteran as President and COO 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22
(Date:12/15/2014)... December 15, 2014 The increase in prevalence ... of the main factors which is contributing to the growth ... the diagnosis and treatment of hearing loss and balance disorders ... three parts - microphone, speaker and amplifier. The global market ... of 6.01% during the period from 2014 to 2019. Some ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Emergo Group, ... in 26 countries in North and South America, Europe, ... responses from industry participants for its 2015 Medical Device ... order to identify upcoming business and market trends as ... , The survey targets areas including:, , ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Kenmode Precision ... the firm as Director of Quality Assurance. He ... quality systems, processes and certifications for manufacturers in the ... posts of Corporate Quality Manager at Sonoco Products Company ... at NetCom, Inc., and Quality Assurance Manager for Prince ...
(Date:12/15/2014)... Metal drilling machines have ... This score indicates that neither buyers nor suppliers have ... have been raising the price of metal drilling machines ... rising demand,” according to IBISWorld business research analyst, Jeffrey ... During the past three years, high price driver volatility ...
Breaking Medicine News(10 mins):Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2Health News:Metal Drilling Machines Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Metal Drilling Machines Procurement Category Market Research Report Now Available from IBISWorld 3
... to excess days off, poor-quality output, study finds , , ... attention deficit hyperactivity disorder (ADHD) miss, on average, more ... to a new global reckoning of the problem. , ... worldwide have ADHD, according to survey data from the ...
... Neck, leg sites similar, but jugular should be choice for ... News) -- There,s little overall difference in infection risk if ... or an upper leg vein in critically ill patients, French ... is less likely to cause infection than the leg catheter. ...
... is not a phrase normally used to describe a ... Tel Aviv University, the chemical industry is a step ... from the School of Chemistry at Tel Aviv University ... certain steps of a complicated chain of chemical reactions ...
... With many Americans eagerly,awaiting some extra cash in their ... time to make an investment in your health. As ... Association and its,3,000 members urge you to invest your ... "What,s more important than investing in your health?" said ...
... Introduces EveryKid(TM), An Organic First For Children,s ... ... food,chemical-free nutrition is ideal to a child,s healthy growth and,development, parents ... of chemical vitamin,isolates. But today, New Chapter -- the leading producer ...
... explain why some nonsmokers contract the disease, study says , , ... increases the risk of lung cancer, even in nonsmokers, researchers ... alpha1-antitrypsin gene double someones risk of developing lung cancer, regardless ... explain why some nonsmokers develop the disease, said study author ...
Cached Medicine News:Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 2Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 3Health News:Dialysis Catheter Placement Makes Little Difference in Infection Risk 2Health News:1 small step for a lab science, 1 green leap for mankind 2Health News:Invest in Your Future With a Spa Visit Today 2Health News:Invest in Your Future With a Spa Visit Today 3Health News:Finally ... A Pure and Perfect Multi-Vitamin for Every Kid 2Health News:Finally ... A Pure and Perfect Multi-Vitamin for Every Kid 3Health News:Common Genetic Variant Tied to Lung Cancer Risk 2Health News:Common Genetic Variant Tied to Lung Cancer Risk 3
Inquire...
QC HGB is an assayed quality control material for Hemocue analyzers. This control is a solution of stabilized human red cells and is available in 3 levels for monitoring analyzer performance at sever...
... a state of the art software package designed ... Optical Laboratory. Designed by a lens manufacturer with ... polycarbonate lenses, Optifacts is designed to help you ... not the way the software dictates., ,Designed specifically ...
VertiGraft allografts for spine surgery deliver the strength adn performance you demand in your procedures and they are backed by quality and safety standards that are unmatched in the industry....
Medicine Products: